(Q26775383)

Nivolumab plus ipilimumab in advanced melanoma

PubMed

volume

4

0 references

issue

5

0 references

page(s)

560-75

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

The blockade of immune checkpoints in cancer immunotherapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Pembrolizumab for the treatment of non-small-cell lung cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Nivolumab in previously untreated melanoma without BRAF mutation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Ipilimumab and its toxicities: a multidisciplinary approach

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Management of immune-related adverse events and kinetics of response with ipilimumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4630514

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

28 November 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Immunologic and clinical effects of targeting PD-1 in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Mitigating the toxic effects of anticancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Anti-CTLA4 antibody-induced lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.LUNGCAN.2015.02.007

7 January 2021

10.3978/J.ISSN.2218-6751.2015.06.06

Identifiers

DOI

1 reference

10.1016/J.LUNGCAN.2015.02.007

1 reference

1 reference

1 reference

PubMed publication ID

26629425

1 reference